Moderna at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Moderna brings 15 presentations to IDWeek 2026 in Washington, and exhibits at Booth 1424, BS 13, BS 14. Its program centres on mRNA vaccines for COVID, flu and RSV, from effectiveness and safety monitoring after authorization to projected public health impact in adults. It also brings community cohort data on respiratory and gut infections in Peru and on norovirus care patterns in US adults.
| Organization | IDWeek 2026 Attendance |
|---|---|
Moderna Cambridge, MA | |
mRNA medicine company whose platform yields vaccines and therapies across infectious disease, cancer immunotherapy, rare disease and autoimmunity. | Booth Exhibiting at Booth 1424, BS 13, BS 14 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Talk Thu Oct 22 2:45pm–3:00pm Talk Sat Oct 24 10:54am–11:06am Efficacy and Immunogenicity of an mRNA-Based Seasonal Influenza Vaccine in Older Adults: A Subanalysis of the Phase 3 FLUENT Trial VaccinesRespiratory infections and COVID-19 Poster Sat Oct 24 12:15pm–1:30pm Characterizing the Symptoms of Infectious Mononucleosis in an Upper Midwest Population, USA Poster Sat Oct 24 12:15pm–1:30pm Comorbidities of Adults with Medically Attended Influenza and COVID-19 Infection in the United States Poster Sat Oct 24 12:15pm–1:30pm Describing Care Setting Patterns for Norovirus Gastroenteritis in US Adults 2019–2024: A MarketScan Database Analysis Poster Sat Oct 24 12:15pm–1:30pm Estimated Impact of Increasing RSV Vaccination Coverage on Burden Among Older Adults in the Veterans Health Administration Poster Sat Oct 24 12:15pm–1:30pm Incidence of Acute Gastroenteritis in a Community Cohort in Peru Poster Sat Oct 24 12:15pm–1:30pm Incidence of Acute Respiratory Infections in a Community Cohort in Peru Poster Sat Oct 24 12:15pm–1:30pm Influenza and COVID-19 Vaccine Coverage Rates among Adults With and Without High-Risk Comorbidities Poster Sat Oct 24 12:15pm–1:30pm Post-Authorization Active Surveillance Safety Study Using Secondary Data to Monitor Real World Safety of mRESVIA® for Respiratory Syncytial Virus in the United States: Interim Descriptive Analyses Poster Sat Oct 24 12:15pm–1:30pm Post-Marketing Safety of an 2024-2025 mRNA-1273 COVID vaccine (mRNA-1273.712): A U.S. Claims-Based Active Surveillance Study (Optum’s de-identified Clinformatics® Data Mart Database and Humana Medicare Advantage Database) Poster Sat Oct 24 12:15pm–1:30pm Projected Public Health Impact of mRNA-1345 Revaccination Strategies in the ACIP-Recommended US Adult Population Poster Sat Oct 24 12:15pm–1:30pm Public Health and Economic Impact of mRNA-1345 Vaccination on RSV Burden in US Adults Using First-Season Real-World Effectiveness Poster Sat Oct 24 12:15pm–1:30pm Real-World Co-administration Patterns of mRNA-1283 COVID-19 Vaccine with Influenza and Other Vaccines in the United States Poster Sat Oct 24 12:15pm–1:30pm Severity of Test-Confirmed HMPV, Influenza, RSV, and SARS-CoV-2 Acute Respiratory Hospitalizations in Adults, 2022-2025 |
Instantly find 20 buyers from Moderna
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction